COVID-19 antibody test performance
In an effort to support the work evaluating technologies for serology (antibody) testing, the lab has developed an interactive webapp to explore the effect of changing prevalence on the population-level performance of these tests.
Because the fraction of people in the general population who have been exposed to COVID-19 (which we call the prevalence) is still low, even antibody tests with high sensitivity and specificity may end up mis-classifying a large number of people. To address this we created an interactive web app that shows the effect of changing the prevalence (as well as the test performance) on the probability that given a positive test you actually have SARS-CoV-2 antibodies. We have included data from other antibody test evaluations as well as state and county-level prevalence values for a geographically-refined interpretation of these results.
miRNA tissue atlas
Good RNA biomarkers tend to be specifically expressed in tissues relevant to the disease under investigation. In collaboration with the van Keuren-Jensen lab at TGen, we have created a human small-RNA tissue atlas. The interactive webapp enables discovery and deeper interrogation of tissue-specific miRNAs to accelerate community efforts to develop informative non-invasive biomarkers of many different diseases.